BD (NYSE:BDX) announced today that it completed the acquisition of smartphone-enabled, at-home medical test developer Scanwell Health.
Financial terms for the transaction were not disclosed. BD expects the acquisition to be immaterial to its fiscal 2022 results, with Scanwell’s financial results set to be reported under BD’s integrated diagnostic solutions business within the life sciences segment.
Franklin Lakes, New Jersey-based BD collaborated with Scanwell in the past on COVID-19 testing, announcing in February that it was working with Scanwell Health to offer its mobile app to pair with the BD Veritor at-home COVID-19 test, which uses a smartphone camera and app to capture and interpret results.
Scanwell will become the digital platform on which BD plans to develop at-home diagnostic tests for a range of infectious diseases, including COVID-19, influenza A+B, group A strep and more, according to a news release.<…